Seubert, Peter

Grant Detail

The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.

Abeta and angiogenesis

Mullan, Michael

1 April 2001 - 30 April 2010
NATIONAL INSTITUTE ON AGING
Total Funding: $ 2,322,764

The over-arching area of enquiry of the original RO1 (AG19250) was to understand the origin of the cerebrovascular abnormalities characteristic of Alzheimer's Disease (AD). Numerous structural and functional cerebromicrovascular abnormalities have been identified in AD subjects, including decreased capillary diameter and microvessel density, thinning of capillary basement membrane, attenuation of capillary endothelium and cerebrovascular muscle atrophy supporting the possibility of an alternation of the angiogenic process in AD brain. Microvessels undergoing angiogenesis and sprouting, normally proliferate by growth of the endothelium, which subsequently secretes the basement membrane. The opposite result has been observed in Alzheimer's disease, where microvessels associated with Abeta deposits displayed non-functional endothelium along with thinning of the basement membrane. To understand how the cerebrovascular pathological abnormalities of AD occur we first focused on the prostaglandin producing pro-inflammatory sPLA2-MAPK-cPLA2-AA-LOX/COX pathway is activated in the vasculature which we have shown is activated by low doses of freshly solubilized Abeta. The specific aims of the current proposal have arisen directly from our observations made in R01 NIA-AG19250 the results of which are detailed below. Observation that the sPLA2-MAPK-cPLA2-AA-LOX-COX pathway is activated in the vasculature by Abeta load us to the question of whether Abeta could stimulate an imflammatory angiogenesis. Surprisingly we found that although at low doses of Abeta there is evidence that Aa can stimulate angiogenesis at higher doses (with greater aggregation of Abeta) a profound anti-angiogenic response occurs. We have explored the anti-angiogenic response of Abeta for two distinct reasons: firstly it could account for some of the pathological cerebrovascular pathologies observed in the course of the AD process and secondly Abeta or related peptides may be a potential candidate for anti-tumor therapies based on it's antiangiogenic properties. The purpose of this proposal is to increase our understanding of how and why Abeta has such potent anti-angiogenic properties.

5 Resulting Publications

• 1.

  2010

  Daniel Paris; Nowel Ganey; Magdalena Banasiak; Vincent Laporte; Nikunj Patel; Myles Mullan; Susan F Murphy; Gi-Taek Yee; Corbin Bachmeier; Christopher Ganey; et al.

  Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 2010;30(34):11251-8.

• 2.

  2005

  Daniel Paris; Ghania Ait-Ghezala; Venkatarajan S Mathura; Nikunj Patel; Amita Quadros; Vincent Laporte; Mike Mullan

  Anti-angiogenic activity of the mutant Dutch A(beta) peptide on human brain microvascular endothelial cells.

  Brain research. Molecular brain research 2005;136(1-2):212-30.

• 3.

  2003

  Daniel Paris; James Humphrey; Amita Quadros; Nikunj Patel; Robert Crescentini; Fiona Crawford; Michael Mullan

  Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation.

  Neurological research 2003;25(6):642-51.

• 4.

  2002

  K P Townsend; D Obregon; A Quadros; N Patel; Ch Volmar; D Paris; M Mullan

  Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature.

  Annals of the New York Academy of Sciences 2002;977():65-76.

• 5.

  2002

  Daniel Paris; Kirk P Townsend; Demian F Obregon; James Humphrey; Michael Mullan

  Pro-inflammatory effect of freshly solubilized beta-amyloid peptides in the brain.

  Prostaglandins & other lipid mediators 2002;70(1-2):1-12.

Scientific Context

This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.